<Summary id="CDR0000258022" LegacyPDQID="3500" ReplacementFor="CDR0000062882"><SummaryMetaData><SummaryType>Treatment</SummaryType><SummaryAudience>Patients</SummaryAudience><SummaryLanguage>English</SummaryLanguage><SummaryDescription>Mycosis fungoides and other cutaneous T-cell lymphomas (including Sézary Syndrome)treatment options include photodynamic therapy, radiation therapy, chemotherapy, immunotherapy, and targeted therapy. Learn more about newly diagnosed and recurrentmycosis fungoides and its treatment in this expert-reviewed summary.</SummaryDescription><SummaryURL xref="https://www.cancer.gov/types/lymphoma/patient/mycosis-fungoides-treatment-pdq">Mycosis Fungoides (Including Sézary Syndrome) (PDQ®): Treatment</SummaryURL><SummaryToggleURL xref="https://www.cancer.gov/types/lymphoma/hp/mycosis-fungoides-treatment-pdq">Mycosis Fungoides (Including Sézary Syndrome) (PDQ®): Treatment</SummaryToggleURL><SummaryEditorialBoard ref="CDR0000028327">PDQ Adult Treatment Editorial Board</SummaryEditorialBoard><MainTopics><TermRef ref="CDR0000038223">mycosis fungoides/Sezary syndrome</TermRef></MainTopics><SummaryAbstract><Para id="_183">This PDQ cancer information summary has current information about the treatment of mycosis fungoides (including Sézary  Syndrome). It is meant to inform and help patients, families, and caregivers. It does not give formal guidelines or recommendations for making decisions about health care.</Para><Para id="_184">Editorial Boards write the PDQ cancer information summaries and keep them up to date. These Boards are made up of experts in cancer treatment and other specialties related to cancer. The summaries are reviewed regularly and changes are made when there is new information. The date on each summary ("Date Last Modified") is the date of the most recent change. The information in this patient summary was taken from the health professional version, which is reviewed regularly and updated as needed, by the PDQ Adult Treatment Editorial Board.</Para></SummaryAbstract><SummaryKeyWords><SummaryKeyWord>mycosis fungoides/Sezary syndrome</SummaryKeyWord></SummaryKeyWords></SummaryMetaData><SummaryTitle>Mycosis Fungoides (Including Sézary Syndrome) Treatment (PDQ®)–Patient Version</SummaryTitle><AltTitle TitleType="Browser">Mycosis Fungoides (Including Sézary Syndrome) Treatment</AltTitle><AltTitle TitleType="CancerTypeHomePage">Mycosis Fungoides (Including Sézary Syndrome) Treatment</AltTitle><SummarySection id="_1"><Title>General Information About Mycosis Fungoides (Including Sézary Syndrome)</Title><SummarySection id="_3"><SectMetaData><SectionType>Organ description</SectionType><SectionType>Cancer description</SectionType></SectMetaData><KeyPoint id="_4">Mycosis fungoides and Sézary syndrome are diseases in which
		  lymphocytes (a type of white blood cell) become malignant
		  (cancerous) and affect the skin.</KeyPoint><Para id="_121">Normally, the <GlossaryTermRef href="CDR0000045622" dictionary="Cancer.gov" audience="Patient">bone marrow</GlossaryTermRef> makes <GlossaryTermRef href="CDR0000765906" dictionary="Cancer.gov" audience="Patient">blood stem cells</GlossaryTermRef> (immature <GlossaryTermRef href="CDR0000046476" dictionary="Cancer.gov" audience="Patient">cells</GlossaryTermRef>) that become mature blood stem cells over time.  A blood stem cell may become a <GlossaryTermRef href="CDR0000046279" dictionary="Cancer.gov" audience="Patient">myeloid</GlossaryTermRef> <GlossaryTermRef href="CDR0000046598" dictionary="Cancer.gov" audience="Patient">stem cell</GlossaryTermRef> or a <GlossaryTermRef href="CDR0000046298" dictionary="Cancer.gov" audience="Patient">lymphoid</GlossaryTermRef> stem cell. A myeloid stem cell becomes a <GlossaryTermRef href="CDR0000046124" dictionary="Cancer.gov" audience="Patient">red blood cell</GlossaryTermRef>, <GlossaryTermRef href="CDR0000045993" dictionary="Cancer.gov" audience="Patient">white blood cell</GlossaryTermRef>, or <GlossaryTermRef href="CDR0000045840" dictionary="Cancer.gov" audience="Patient">platelet</GlossaryTermRef>.  A lymphoid stem cell becomes a <GlossaryTermRef href="CDR0000302475" dictionary="Cancer.gov" audience="Patient">lymphoblast</GlossaryTermRef> and then one of three types of <GlossaryTermRef href="CDR0000045765" dictionary="Cancer.gov" audience="Patient">lymphocytes</GlossaryTermRef> (white blood cells):</Para><ItemizedList id="_122" Style="bullet"><ListItem><GlossaryTermRef href="CDR0000045611" dictionary="Cancer.gov" audience="Patient">B-cell</GlossaryTermRef> lymphocytes that make <GlossaryTermRef href="CDR0000044918" dictionary="Cancer.gov" audience="Patient">antibodies</GlossaryTermRef> to help fight <GlossaryTermRef href="CDR0000045364" dictionary="Cancer.gov" audience="Patient">infection</GlossaryTermRef>.</ListItem><ListItem><GlossaryTermRef href="CDR0000044928" dictionary="Cancer.gov" audience="Patient">T-cell</GlossaryTermRef> lymphocytes that help <GlossaryTermRef href="CDR0000044953" dictionary="Cancer.gov" audience="Patient">B-lymphocytes</GlossaryTermRef> make the antibodies that help fight infection.</ListItem><ListItem><GlossaryTermRef href="CDR0000044062" dictionary="Cancer.gov" audience="Patient">Natural killer cells</GlossaryTermRef> that attack <GlossaryTermRef href="CDR0000045333" dictionary="Cancer.gov" audience="Patient">cancer</GlossaryTermRef>  cells and <GlossaryTermRef href="CDR0000045941" dictionary="Cancer.gov" audience="Patient">viruses</GlossaryTermRef>.</ListItem></ItemizedList><MediaLink ref="CDR0000526538" type="image/jpeg" alt="Blood cell development; drawing shows the steps a blood stem cell goes through to become a red blood cell, platelet, or white blood cell. A myeloid stem cell becomes a red blood cell, a platelet, or a myeloblast, which then becomes a granulocyte (the types of granulocytes are eosinophils, basophils, and neutrophils). A lymphoid stem cell becomes a lymphoblast and then becomes a B-lymphocyte, T-lymphocyte, or natural killer cell." language="en" placement="image-center" id="_145"><Caption language="en">Blood cell development. A blood stem cell goes through several steps to become a red blood cell, platelet, or white blood cell. </Caption></MediaLink><Para id="_123">In mycosis fungoides, T-cell lymphocytes become cancerous and affect  the skin. When these lymphocytes occur in the <GlossaryTermRef href="CDR0000270735" dictionary="Cancer.gov" audience="Patient">blood</GlossaryTermRef>, they are called Sézary cells. In <GlossaryTermRef href="CDR0000045878" dictionary="Cancer.gov" audience="Patient">Sézary syndrome</GlossaryTermRef>, cancerous T-cell lymphocytes affect the skin and large numbers of Sézary cells are found in the blood.</Para></SummarySection><SummarySection id="_9"><SectMetaData><SectionType>Cancer description</SectionType></SectMetaData><KeyPoint id="_10">Mycosis fungoides and Sézary syndrome are types of cutaneous T-cell lymphoma. </KeyPoint><Para id="_11"> Mycosis fungoides and Sézary syndrome are the two most common types of cutaneous T-cell
		lymphoma (a type of <GlossaryTermRef href="CDR0000045148" dictionary="Cancer.gov" audience="Patient">non-Hodgkin lymphoma</GlossaryTermRef>). For information about other types of <GlossaryTermRef href="CDR0000445084" dictionary="Cancer.gov" audience="Patient">skin cancer</GlossaryTermRef> or non-Hodgkin lymphoma, see the following <GlossaryTermRef href="CDR0000044271" dictionary="Cancer.gov" audience="Patient">PDQ</GlossaryTermRef> summaries:</Para><ItemizedList id="_106" Style="bullet"><ListItem><SummaryRef href="CDR0000062958" url="/types/lymphoma/patient/adult-nhl-treatment-pdq">Adult Non-Hodgkin Lymphoma Treatment</SummaryRef></ListItem><ListItem><SummaryRef href="CDR0000258035" url="/types/skin/patient/skin-treatment-pdq">Skin Cancer Treatment</SummaryRef></ListItem><ListItem><SummaryRef href="CDR0000062713" url="/types/skin/patient/melanoma-treatment-pdq">Melanoma Treatment</SummaryRef></ListItem><ListItem><SummaryRef href="CDR0000442381" url="/types/soft-tissue-sarcoma/patient/kaposi-treatment-pdq">Kaposi Sarcoma Treatment</SummaryRef></ListItem></ItemizedList></SummarySection><SummarySection id="_13"><SectMetaData><SectionType>Cancer description</SectionType><SectionType>Symptoms</SectionType></SectMetaData><KeyPoint id="_14">A sign of mycosis fungoides is a red rash on the skin.</KeyPoint><Para id="_108">Mycosis fungoides may go through  the following phases:</Para><ItemizedList id="_124" Style="bullet"><ListItem><GlossaryTermRef href="CDR0000439417" dictionary="Cancer.gov" audience="Patient">Premycotic phase</GlossaryTermRef>: A scaly, red rash in areas of the body that usually are not exposed to the sun. This rash does not cause <GlossaryTermRef href="CDR0000045022" dictionary="Cancer.gov" audience="Patient">symptoms</GlossaryTermRef> and may last for months or years. It is hard to <GlossaryTermRef href="CDR0000046450" dictionary="Cancer.gov" audience="Patient">diagnose</GlossaryTermRef> the rash as mycosis fungoides during this phase.</ListItem><ListItem><GlossaryTermRef href="CDR0000729587" dictionary="Cancer.gov" audience="Patient">Patch</GlossaryTermRef> phase: Thin, reddened, <GlossaryTermRef href="CDR0000462675" dictionary="Cancer.gov" audience="Patient">eczema</GlossaryTermRef>-like rash.</ListItem><ListItem><GlossaryTermRef href="CDR0000439411" dictionary="Cancer.gov" audience="Patient">Plaque</GlossaryTermRef> phase: Small raised bumps (<GlossaryTermRef href="CDR0000729589" dictionary="Cancer.gov" audience="Patient">papules</GlossaryTermRef>) or hardened <GlossaryTermRef href="CDR0000046324" dictionary="Cancer.gov" audience="Patient">lesions</GlossaryTermRef> on the skin, which may be reddened. </ListItem><ListItem><GlossaryTermRef href="CDR0000046634" dictionary="Cancer.gov" audience="Patient">Tumor</GlossaryTermRef> phase: Tumors form on the skin. These tumors may develop <GlossaryTermRef href="CDR0000269469" dictionary="Cancer.gov" audience="Patient">ulcers</GlossaryTermRef> and the skin may get infected.</ListItem></ItemizedList><Para id="_173">Check with your doctor if you have any of these <GlossaryTermRef href="CDR0000750109" dictionary="Cancer.gov" audience="Patient">signs</GlossaryTermRef>.</Para></SummarySection><SummarySection id="_125"><SectMetaData><SectionType>Cancer description</SectionType></SectMetaData><KeyPoint id="_126">In Sézary syndrome, cancerous T-cells are found in the blood.</KeyPoint><Para id="_127">Also, skin all over the body is reddened, itchy, peeling, and painful. There may also be patches, plaques, or tumors on the skin.  It is not known if Sézary syndrome is an advanced form of mycosis fungoides or a separate disease.</Para></SummarySection><SummarySection id="_16"><SectMetaData><SectionType>Diagnostic tests</SectionType></SectMetaData><KeyPoint id="_17">Tests that examine the skin and blood are used to diagnose mycosis fungoides and Sézary syndrome.</KeyPoint><Para id="_18">The following tests and procedures may be used:</Para><ItemizedList id="_19" Style="bullet"> 
		  <ListItem><Strong><GlossaryTermRef href="CDR0000270871" dictionary="Cancer.gov" audience="Patient">Physical exam</GlossaryTermRef> and <GlossaryTermRef href="CDR0000798522" dictionary="Cancer.gov" audience="Patient">health history</GlossaryTermRef></Strong>: An exam of the body to check general signs of health, including checking for signs of disease, such as lumps, the number and type of skin lesions, or anything else that seems unusual. Pictures of the skin and a history of the patient's health habits and  past illnesses and treatments will also be taken.</ListItem><ListItem><Strong><GlossaryTermRef href="CDR0000729979" dictionary="Cancer.gov" audience="Patient">Complete blood count with differential</GlossaryTermRef></Strong>: A procedure in which a sample of blood is drawn and checked for the following:  
   <ItemizedList id="_114" Style="dash"><ListItem>The number of red blood cells and platelets.</ListItem><ListItem>The number and type of white blood cells.</ListItem><ListItem>The amount of <GlossaryTermRef href="CDR0000045108" dictionary="Cancer.gov" audience="Patient">hemoglobin</GlossaryTermRef> (the <GlossaryTermRef href="CDR0000046092" dictionary="Cancer.gov" audience="Patient">protein</GlossaryTermRef> that carries <GlossaryTermRef href="CDR0000538149" dictionary="Cancer.gov" audience="Patient">oxygen</GlossaryTermRef>) in the red blood cells. 
   </ListItem><ListItem>The portion of the blood sample made up of red blood cells.</ListItem></ItemizedList><MediaLink ref="CDR0000526546" type="image/jpeg" alt="Complete blood count (CBC); left panel shows blood being drawn from a vein on the inside of the elbow using a tube attached to a syringe; right panel shows a laboratory test tube with blood cells separated into layers: plasma, white blood cells, platelets, and red blood cells." language="en" placement="image-center" id="_140"><Caption language="en">Complete blood count (CBC). Blood is collected by inserting a needle into a vein and allowing the blood to flow into a tube. The blood sample is sent to the laboratory and the red blood cells, white blood cells, and platelets are counted.  The CBC is used to test for, diagnose, and monitor many different conditions.</Caption></MediaLink></ListItem><ListItem><Strong>Sézary blood cell count</Strong>: A procedure in which a sample of blood is viewed under a <GlossaryTermRef href="CDR0000638184" dictionary="Cancer.gov" audience="Patient">microscope</GlossaryTermRef> to count the number of Sézary cells.</ListItem> 
		  <ListItem><Strong><GlossaryTermRef href="CDR0000759626" dictionary="Cancer.gov" audience="Patient">HIV test</GlossaryTermRef></Strong>: A test to measure the level of <GlossaryTermRef href="CDR0000045711" dictionary="Cancer.gov" audience="Patient">HIV antibodies</GlossaryTermRef> in a sample of blood.  Antibodies are made by the body when it is invaded by a <GlossaryTermRef href="CDR0000698772" dictionary="Cancer.gov" audience="Patient">foreign</GlossaryTermRef> substance. A high level of HIV antibodies may mean the body has been infected with HIV.</ListItem><ListItem><Strong>Skin <GlossaryTermRef href="CDR0000045164" dictionary="Cancer.gov" audience="Patient">biopsy</GlossaryTermRef></Strong>: The removal of cells or <GlossaryTermRef href="CDR0000046683" dictionary="Cancer.gov" audience="Patient">tissues</GlossaryTermRef> so they can be viewed under a microscope to check for signs of cancer. The doctor may remove a growth from the skin, which will be examined by a <GlossaryTermRef href="CDR0000046244" dictionary="Cancer.gov" audience="Patient">pathologist</GlossaryTermRef>.  More than one skin biopsy may be needed to diagnose mycosis fungoides. Other tests that may be done on the cells or tissue sample include the following:<ItemizedList id="_210" Style="bullet"><ListItem> <Strong><GlossaryTermRef href="CDR0000341450" dictionary="Cancer.gov" audience="Patient">Immunophenotyping</GlossaryTermRef></Strong>: A <GlossaryTermRef href="CDR0000046590" dictionary="Cancer.gov" audience="Patient">laboratory test</GlossaryTermRef> that uses antibodies to identify cancer cells based on the types of <GlossaryTermRef href="CDR0000046086" dictionary="Cancer.gov" audience="Patient">antigens</GlossaryTermRef> or <GlossaryTermRef href="CDR0000045776" dictionary="Cancer.gov" audience="Patient">markers</GlossaryTermRef> on the surface of the cells. This test is used to help diagnose specific types of lymphoma.</ListItem><ListItem><Strong><GlossaryTermRef href="CDR0000335066" dictionary="Cancer.gov" audience="Patient">Flow cytometry</GlossaryTermRef></Strong>: A laboratory test that measures the number of cells in a sample, the percentage of live cells in a sample, and certain characteristics of the cells, such as size, shape, and the presence of tumor (or other) <GlossaryTermRef href="CDR0000046636" dictionary="Cancer.gov" audience="Patient">markers</GlossaryTermRef> on the cell surface. The cells from a sample of a patient’s blood, bone marrow, or other tissue are stained with a fluorescent dye, placed in a <GlossaryTermRef href="CDR0000044669" dictionary="Cancer.gov" audience="Patient">fluid</GlossaryTermRef>, and then passed one at a time through a beam of light. The test results are based on how the cells that were stained with the fluorescent dye react to the beam of light. This test is used to help diagnose and manage certain types of cancers, such as <GlossaryTermRef href="CDR0000045343" dictionary="Cancer.gov" audience="Patient">leukemia</GlossaryTermRef> and lymphoma.</ListItem><ListItem><Strong><GlossaryTermRef href="CDR0000780791" dictionary="Cancer.gov" audience="Patient">T-cell receptor (TCR) gene rearrangement test</GlossaryTermRef></Strong>: A laboratory test in which cells in a sample of blood or bone marrow are checked to see if there are certain changes in the <GlossaryTermRef href="CDR0000045693" dictionary="Cancer.gov" audience="Patient">genes</GlossaryTermRef> that make <GlossaryTermRef href="CDR0000044958" dictionary="Cancer.gov" audience="Patient">receptors</GlossaryTermRef> on T cells (white blood cells). Testing for these gene changes can tell whether large numbers of T cells with a certain <GlossaryTermRef href="CDR0000787980" dictionary="Cancer.gov" audience="Patient">T-cell receptor</GlossaryTermRef> are being made.</ListItem></ItemizedList></ListItem>
		   
		</ItemizedList></SummarySection><SummarySection id="_20"><SectMetaData><SectionType>Prognostic factors</SectionType></SectMetaData><KeyPoint id="_21">Certain factors affect prognosis (chance
		  of recovery) and treatment options.</KeyPoint><Para id="_103">The <GlossaryTermRef href="CDR0000045849" dictionary="Cancer.gov" audience="Patient">prognosis</GlossaryTermRef> and treatment options depend on the following:</Para><ItemizedList id="_104" Style="bullet"><ListItem>The <GlossaryTermRef href="CDR0000045885" dictionary="Cancer.gov" audience="Patient">stage</GlossaryTermRef> of the cancer.</ListItem><ListItem>The type of lesion (patches, plaques, or tumors).</ListItem><ListItem>The patient's age and sex.</ListItem></ItemizedList><Para id="_119">Mycosis fungoides and Sézary syndrome are hard to <GlossaryTermRef href="CDR0000318813" dictionary="Cancer.gov" audience="Patient">cure</GlossaryTermRef>. Treatment  is usually <GlossaryTermRef href="CDR0000045815" dictionary="Cancer.gov" audience="Patient">palliative</GlossaryTermRef>, to relieve symptoms and improve the <GlossaryTermRef href="CDR0000045417" dictionary="Cancer.gov" audience="Patient">quality of life</GlossaryTermRef>. Patients with earlystage disease may live many years.</Para></SummarySection></SummarySection><SummarySection id="_26"><Title>Stages of Mycosis Fungoides (Including Sézary Syndrome) </Title><SummarySection id="_27"><SectMetaData><SectionType>Diagnostic tests</SectionType></SectMetaData><KeyPoint id="_28">After mycosis fungoides and Sézary syndrome have been
		  diagnosed, tests are done to find out if cancer cells have spread from the skin to other parts of the body.</KeyPoint><Para id="_29">The process used to find out if <GlossaryTermRef href="CDR0000045333" dictionary="Cancer.gov" audience="Patient">cancer</GlossaryTermRef> has spread from the skin to other parts
		  of the body is called <GlossaryTermRef href="CDR0000046597" dictionary="Cancer.gov" audience="Patient">staging</GlossaryTermRef>. The
		  information gathered from the staging process determines the
		  <GlossaryTermRef href="CDR0000045885" dictionary="Cancer.gov" audience="Patient">stage</GlossaryTermRef> of the disease. It is
		  important to know the stage in order to plan treatment.</Para><Para id="_182">The following
		  procedures may be used in the staging process:</Para><ItemizedList id="_30" Style="bullet"> 
		  <ListItem><Strong><GlossaryTermRef href="CDR0000304687" dictionary="Cancer.gov" audience="Patient">Chest x-ray</GlossaryTermRef></Strong>: An <GlossaryTermRef href="CDR0000045944" dictionary="Cancer.gov" audience="Patient">x-ray</GlossaryTermRef> of the <GlossaryTermRef href="CDR0000257523" dictionary="Cancer.gov" audience="Patient">organs</GlossaryTermRef> and bones inside the chest.  An x-ray is a type of energy beam that can go through the body and onto film, making a picture of areas inside the body.</ListItem><ListItem><Strong><GlossaryTermRef href="CDR0000046033" dictionary="Cancer.gov" audience="Patient">CT scan</GlossaryTermRef> (CAT scan)</Strong>: A procedure that makes a series of detailed pictures of areas inside the body, such as the <GlossaryTermRef href="CDR0000045762" dictionary="Cancer.gov" audience="Patient">lymph nodes</GlossaryTermRef>, chest, <GlossaryTermRef href="CDR0000045070" dictionary="Cancer.gov" audience="Patient">abdomen</GlossaryTermRef>, and <GlossaryTermRef href="CDR0000046246" dictionary="Cancer.gov" audience="Patient">pelvis</GlossaryTermRef>, taken from different angles.  The pictures are made by a computer linked to an x-ray machine. A <GlossaryTermRef href="CDR0000409764" dictionary="Cancer.gov" audience="Patient">dye</GlossaryTermRef> may be <GlossaryTermRef href="CDR0000044678" dictionary="Cancer.gov" audience="Patient">injected</GlossaryTermRef> into a <GlossaryTermRef href="CDR0000476471" dictionary="Cancer.gov" audience="Patient">vein</GlossaryTermRef> or swallowed to help the organs or <GlossaryTermRef href="CDR0000046683" dictionary="Cancer.gov" audience="Patient">tissues</GlossaryTermRef> show up more clearly.  This procedure is also called computed tomography, computerized tomography, or computerized axial tomography. </ListItem><ListItem><Strong><GlossaryTermRef href="CDR0000046140" dictionary="Cancer.gov" audience="Patient">PET scan</GlossaryTermRef> (positron emission tomography scan)</Strong>: A procedure to find <GlossaryTermRef href="CDR0000045772" dictionary="Cancer.gov" audience="Patient">malignant</GlossaryTermRef> <GlossaryTermRef href="CDR0000046634" dictionary="Cancer.gov" audience="Patient">tumor</GlossaryTermRef> <GlossaryTermRef href="CDR0000046476" dictionary="Cancer.gov" audience="Patient">cells</GlossaryTermRef> in the body.  A small amount of <GlossaryTermRef href="CDR0000046550" dictionary="Cancer.gov" audience="Patient">radioactive</GlossaryTermRef> <GlossaryTermRef href="CDR0000044033" dictionary="Cancer.gov" audience="Patient">glucose</GlossaryTermRef> (sugar) is injected into a vein.  The PET <GlossaryTermRef href="CDR0000386220" dictionary="Cancer.gov" audience="Patient">scanner</GlossaryTermRef> rotates around the body and makes a picture of where glucose is being used in the body.  Malignant tumor cells show up brighter in the picture because they are more active and take up more glucose than normal cells do.</ListItem><ListItem> <Strong><GlossaryTermRef href="CDR0000793499" dictionary="Cancer.gov" audience="Patient">Lymph node biopsy</GlossaryTermRef></Strong>: The removal of all or part of a lymph node. A <GlossaryTermRef href="CDR0000046244" dictionary="Cancer.gov" audience="Patient">pathologist</GlossaryTermRef> views the lymph node tissue under a <GlossaryTermRef href="CDR0000638184" dictionary="Cancer.gov" audience="Patient">microscope</GlossaryTermRef> to check for cancer cells.</ListItem> 
		<ListItem><Strong><GlossaryTermRef href="CDR0000669655" dictionary="Cancer.gov" audience="Patient">Bone marrow aspiration and biopsy</GlossaryTermRef></Strong>: The removal of <GlossaryTermRef href="CDR0000045622" dictionary="Cancer.gov" audience="Patient">bone marrow</GlossaryTermRef> and a small piece of bone by inserting a hollow needle into the hipbone or <GlossaryTermRef href="CDR0000549425" dictionary="Cancer.gov" audience="Patient">breastbone</GlossaryTermRef>. A pathologist views the bone marrow and bone under a microscope to look for signs of cancer.</ListItem></ItemizedList></SummarySection><SummarySection id="_146"><KeyPoint id="_147">There are three ways that cancer spreads in the body.</KeyPoint><Para id="_146_md_69">Cancer can spread through <GlossaryTermRef href="CDR0000046683" dictionary="Cancer.gov" audience="Patient">tissue</GlossaryTermRef>, the <GlossaryTermRef href="CDR0000045764" dictionary="Cancer.gov" audience="Patient">lymph system</GlossaryTermRef>, and the <GlossaryTermRef href="CDR0000270735" dictionary="Cancer.gov" audience="Patient">blood</GlossaryTermRef>:</Para><ItemizedList id="_146_md_70" Style="bullet"><ListItem>Tissue. The cancer spreads from where it began by growing into nearby areas.
</ListItem><ListItem>Lymph system. The cancer spreads from where it began by getting into the lymph system. The cancer travels through the <GlossaryTermRef href="CDR0000269462" dictionary="Cancer.gov" audience="Patient">lymph vessels</GlossaryTermRef> to other parts of the body.
</ListItem><ListItem>Blood. The cancer spreads from where it began by getting into the blood. The cancer travels through the <GlossaryTermRef href="CDR0000045020" dictionary="Cancer.gov" audience="Patient">blood vessels</GlossaryTermRef> to other parts of the body.
</ListItem></ItemizedList></SummarySection><SummarySection id="_179"><KeyPoint id="_180">Cancer may spread from where it began to other parts of the body.</KeyPoint><Para id="_179_md_66">When cancer spreads to another part of the body, it is called <GlossaryTermRef href="CDR0000046710" dictionary="Cancer.gov" audience="Patient">metastasis</GlossaryTermRef>. Cancer cells break away from where they began (the <GlossaryTermRef href="CDR0000045847" dictionary="Cancer.gov" audience="Patient">primary tumor</GlossaryTermRef>) and travel through the lymph system or blood.</Para><ItemizedList id="_179_md_67" Style="bullet"><ListItem>Lymph system. The cancer gets into the lymph system, travels through the lymph vessels, and forms a <GlossaryTermRef href="CDR0000046634" dictionary="Cancer.gov" audience="Patient">tumor</GlossaryTermRef> (<GlossaryTermRef href="CDR0000044058" dictionary="Cancer.gov" audience="Patient">metastatic</GlossaryTermRef> tumor) in another part of the body.</ListItem><ListItem>Blood. The cancer gets into the blood, travels through the blood vessels, and forms a tumor (metastatic tumor) in another part of the body.</ListItem></ItemizedList><Para id="_181">The metastatic tumor is the same type of cancer as the primary tumor. For example, if  <GlossaryTermRef href="CDR0000045794" dictionary="Cancer.gov" audience="Patient">mycosis fungoides</GlossaryTermRef> spreads to the <GlossaryTermRef href="CDR0000046312" dictionary="Cancer.gov" audience="Patient">liver</GlossaryTermRef>, the cancer cells in the liver are actually mycosis fungoides cells. The disease is metastatic mycosis fungoides, not liver cancer.</Para><EmbeddedVideo id="_195" ref="CDR0000787719" hosting="youtube" unique_id="fQwar_-QdiQ" language="en" audience="Patients" template="Video75NoTitle"><VideoTitle>metastasis: how cancer spreads</VideoTitle><Caption language="en">Many cancer deaths are caused when cancer moves from the original tumor and spreads to other tissues and organs. This is called metastatic cancer. This animation shows how cancer cells travel from the place in the body where they first formed to other parts of the body.</Caption></EmbeddedVideo></SummarySection><SummarySection id="_31"><SectMetaData><SectionType>Classification by stage</SectionType></SectMetaData><KeyPoint id="_32">The following stages are used for mycosis fungoides and
		  Sézary syndrome:</KeyPoint><SummarySection id="_33"><KeyPoint id="_34">Stage I Mycosis Fungoides</KeyPoint><Para id="_211"><GlossaryTermRef href="CDR0000454834" dictionary="Cancer.gov" audience="Patient">Stage I</GlossaryTermRef> is divided into stages IA and IB as follows:</Para><ItemizedList id="_212" Style="bullet" Compact="No">
     <ListItem>Stage IA: <GlossaryTermRef href="CDR0000729587" dictionary="Cancer.gov" audience="Patient">Patches</GlossaryTermRef>, <GlossaryTermRef href="CDR0000729589" dictionary="Cancer.gov" audience="Patient">papules</GlossaryTermRef>, and/or <GlossaryTermRef href="CDR0000439411" dictionary="Cancer.gov" audience="Patient">plaques</GlossaryTermRef> cover less than 10% of the skin surface.</ListItem><ListItem>Stage IB: Patches, papules, and/or plaques cover 10% or more of the skin surface.</ListItem></ItemizedList><Para id="_213">There may be a low number of Sézary <GlossaryTermRef href="CDR0000046476" dictionary="Cancer.gov" audience="Patient">cells</GlossaryTermRef> in the <GlossaryTermRef href="CDR0000270735" dictionary="Cancer.gov" audience="Patient">blood</GlossaryTermRef>.</Para></SummarySection><SummarySection id="_37"><KeyPoint id="_38">Stage II Mycosis Fungoides</KeyPoint><Para id="_214"><GlossaryTermRef href="CDR0000454837" dictionary="Cancer.gov" audience="Patient">Stage II</GlossaryTermRef> is divided into stages IIA and IIB as follows:</Para><ItemizedList id="_215" Style="bullet" Compact="No">
     <ListItem>Stage IIA: <GlossaryTermRef href="CDR0000729587" dictionary="Cancer.gov" audience="Patient">Patches</GlossaryTermRef>, <GlossaryTermRef href="CDR0000729589" dictionary="Cancer.gov" audience="Patient">papules</GlossaryTermRef>, and/or <GlossaryTermRef href="CDR0000439411" dictionary="Cancer.gov" audience="Patient">plaques</GlossaryTermRef> cover any amount of skin surface. <GlossaryTermRef href="CDR0000045762" dictionary="Cancer.gov" audience="Patient">Lymph nodes</GlossaryTermRef> are <GlossaryTermRef href="CDR0000044636" dictionary="Cancer.gov" audience="Patient">abnormal</GlossaryTermRef>, but they are not cancerous.</ListItem><ListItem>	Stage IIB: One or more <GlossaryTermRef href="CDR0000046634" dictionary="Cancer.gov" audience="Patient">tumors</GlossaryTermRef> that are 1 <GlossaryTermRef href="CDR0000354457" dictionary="Cancer.gov" audience="Patient">centimeter</GlossaryTermRef> or larger are found on the skin. Lymph nodes may be abnormal, but they are not cancerous.</ListItem></ItemizedList><Para id="_216">There may be a low number of Sézary <GlossaryTermRef href="CDR0000046476" dictionary="Cancer.gov" audience="Patient">cells</GlossaryTermRef> in the <GlossaryTermRef href="CDR0000270735" dictionary="Cancer.gov" audience="Patient">blood</GlossaryTermRef>.</Para></SummarySection><SummarySection id="_41"><KeyPoint id="_42">Stage III Mycosis Fungoides</KeyPoint><Para id="_217">In <GlossaryTermRef href="CDR0000454840" dictionary="Cancer.gov" audience="Patient">stage III</GlossaryTermRef>, 80% or more of the skin surface is reddened and may have <GlossaryTermRef href="CDR0000729587" dictionary="Cancer.gov" audience="Patient">patches</GlossaryTermRef>, <GlossaryTermRef href="CDR0000729589" dictionary="Cancer.gov" audience="Patient">papules</GlossaryTermRef>, <GlossaryTermRef href="CDR0000439411" dictionary="Cancer.gov" audience="Patient">plaques</GlossaryTermRef>, or <GlossaryTermRef href="CDR0000046634" dictionary="Cancer.gov" audience="Patient">tumors</GlossaryTermRef>. <GlossaryTermRef href="CDR0000045762" dictionary="Cancer.gov" audience="Patient">Lymph nodes</GlossaryTermRef> may be <GlossaryTermRef href="CDR0000044636" dictionary="Cancer.gov" audience="Patient">abnormal</GlossaryTermRef>, but they are not cancerous.</Para><Para id="_218">There may be a low number of Sézary <GlossaryTermRef href="CDR0000046476" dictionary="Cancer.gov" audience="Patient">cells</GlossaryTermRef> in the <GlossaryTermRef href="CDR0000270735" dictionary="Cancer.gov" audience="Patient">blood</GlossaryTermRef>.</Para></SummarySection><SummarySection id="_221"><KeyPoint id="_222">Stage IV Mycosis Fungoides/Sézary Syndrome</KeyPoint><Para id="_223">When there is a high number of Sézary cells in the blood, the disease is called <GlossaryTermRef href="CDR0000045878" dictionary="Cancer.gov" audience="Patient">Sézary syndrome</GlossaryTermRef>.</Para><Para id="_219"><GlossaryTermRef href="CDR0000454841" dictionary="Cancer.gov" audience="Patient">Stage IV</GlossaryTermRef> is divided into stages IVA1, IVA2, and IVB as follows:</Para><ItemizedList id="_220" Style="bullet" Compact="No">
     <ListItem>Stage IVA1: <GlossaryTermRef href="CDR0000729587" dictionary="Cancer.gov" audience="Patient">Patches</GlossaryTermRef>, <GlossaryTermRef href="CDR0000729589" dictionary="Cancer.gov" audience="Patient">papules</GlossaryTermRef>, <GlossaryTermRef href="CDR0000439411" dictionary="Cancer.gov" audience="Patient">plaques</GlossaryTermRef>, or <GlossaryTermRef href="CDR0000046634" dictionary="Cancer.gov" audience="Patient">tumors</GlossaryTermRef> may cover any amount of the skin surface, and 80% or more of the skin surface may be reddened. The <GlossaryTermRef href="CDR0000045762" dictionary="Cancer.gov" audience="Patient">lymph nodes</GlossaryTermRef> may be <GlossaryTermRef href="CDR0000044636" dictionary="Cancer.gov" audience="Patient">abnormal</GlossaryTermRef>, but they are not cancerous. There is a high number of Sézary <GlossaryTermRef href="CDR0000046476" dictionary="Cancer.gov" audience="Patient">cells</GlossaryTermRef> in the <GlossaryTermRef href="CDR0000270735" dictionary="Cancer.gov" audience="Patient">blood</GlossaryTermRef>.</ListItem><ListItem>Stage IVA2: Patches, papules, plaques, or tumors may cover any amount of the skin surface, and 80% or more of the skin surface may be reddened. The lymph nodes are very abnormal, or <GlossaryTermRef href="CDR0000045333" dictionary="Cancer.gov" audience="Patient">cancer</GlossaryTermRef> has formed in the lymph nodes. There may be a high number of Sézary cells in the blood.</ListItem><ListItem>Stage IVB: Cancer has spread to other <GlossaryTermRef href="CDR0000257523" dictionary="Cancer.gov" audience="Patient">organs</GlossaryTermRef> in the body, such as the <GlossaryTermRef href="CDR0000046593" dictionary="Cancer.gov" audience="Patient">spleen</GlossaryTermRef> or <GlossaryTermRef href="CDR0000046312" dictionary="Cancer.gov" audience="Patient">liver</GlossaryTermRef>. Patches, papules, plaques, or tumors may cover any amount of the skin surface, and 80% or more of the skin surface may be reddened. The lymph nodes may be abnormal or cancerous. There may be a high number of Sézary cells in the blood.</ListItem></ItemizedList></SummarySection></SummarySection><SummarySection id="_249"><KeyPoint id="_250">Mycosis fungoides and     
		Sézary syndrome can recur
		(come back) after they have been treated.</KeyPoint><Para id="_251">Mycosis fungoides and     
		<GlossaryTermRef href="CDR0000045878" dictionary="Cancer.gov" audience="Patient">Sézary syndrome</GlossaryTermRef> may come back
		in the skin or in other parts of the body, such as the <GlossaryTermRef href="CDR0000046593" dictionary="Cancer.gov" audience="Patient">spleen</GlossaryTermRef> or liver.</Para></SummarySection></SummarySection><SummarySection id="_50"><Title>Treatment Option Overview</Title><SummarySection id="_51"><SectMetaData><SectionType>Standard treatment</SectionType></SectMetaData><KeyPoint id="_52">There are different types of treatment for patients with
		  mycosis fungoides and   cancer. </KeyPoint><Para id="_53">Different types of treatment are available for patients with
		  <GlossaryTermRef href="CDR0000045794" dictionary="Cancer.gov" audience="Patient">mycosis fungoides</GlossaryTermRef> and
		  . Some treatments are
		  <GlossaryTermRef href="CDR0000044930" dictionary="Cancer.gov" audience="Patient">standard</GlossaryTermRef> (the currently used treatment), and some are being tested in
		  <GlossaryTermRef href="CDR0000045961" dictionary="Cancer.gov" audience="Patient">clinical trials</GlossaryTermRef>. A
		  treatment clinical trial is a <GlossaryTermRef href="CDR0000651211" dictionary="Cancer.gov" audience="Patient">research study</GlossaryTermRef> meant to help improve current
		  treatments or obtain information on new treatments for patients with
		  <GlossaryTermRef href="CDR0000045333" dictionary="Cancer.gov" audience="Patient">cancer</GlossaryTermRef>. When clinical trials show that
		  a new treatment is better than the standard
		  treatment, the new treatment may become the standard treatment.       Patients may want to think about taking part in a clinical trial. Some clinical trials are open only to patients who have not started treatment.

		  </Para></SummarySection><SummarySection id="_233"><SectMetaData><SectionType>Standard treatment</SectionType></SectMetaData><KeyPoint id="_56">Seven types of standard treatment are used:</KeyPoint><SummarySection id="_57"><KeyPoint id="_58">Photodynamic therapy</KeyPoint><Para id="_120"><GlossaryTermRef href="CDR0000045238" dictionary="Cancer.gov" audience="Patient">Photodynamic therapy</GlossaryTermRef> is a cancer treatment that uses a <GlossaryTermRef href="CDR0000348921" dictionary="Cancer.gov" audience="Patient">drug</GlossaryTermRef> and a certain type of <GlossaryTermRef href="CDR0000045748" dictionary="Cancer.gov" audience="Patient">laser</GlossaryTermRef> light to kill cancer <GlossaryTermRef href="CDR0000046476" dictionary="Cancer.gov" audience="Patient">cells</GlossaryTermRef>. A drug that is not active until it is exposed to light is <GlossaryTermRef href="CDR0000044678" dictionary="Cancer.gov" audience="Patient">injected</GlossaryTermRef> into a <GlossaryTermRef href="CDR0000476471" dictionary="Cancer.gov" audience="Patient">vein</GlossaryTermRef>. The drug collects more in cancer cells than in normal cells. For <GlossaryTermRef href="CDR0000445084" dictionary="Cancer.gov" audience="Patient">skin cancer</GlossaryTermRef>, laser light is shined onto the skin and the drug becomes active and kills the cancer cells. Photodynamic therapy causes little damage to healthy <GlossaryTermRef href="CDR0000046683" dictionary="Cancer.gov" audience="Patient">tissue</GlossaryTermRef>. Patients undergoing photodynamic therapy will need to limit  the amount of time spent in sunlight. There are different types of photodynamic therapy:</Para><ItemizedList id="_224" Style="bullet" Compact="No"><ListItem>In <GlossaryTermRef href="CDR0000439423" dictionary="Cancer.gov" audience="Patient">psoralen and ultraviolet A (PUVA) therapy</GlossaryTermRef>, the  patient receives a drug
			 called <GlossaryTermRef href="CDR0000044900" dictionary="Cancer.gov" audience="Patient">psoralen</GlossaryTermRef> and then
			 <GlossaryTermRef href="CDR0000666694" dictionary="Cancer.gov" audience="Patient">ultraviolet A radiation</GlossaryTermRef> is directed to
			 the skin. </ListItem><ListItem>In <GlossaryTermRef href="CDR0000403135" dictionary="Cancer.gov" audience="Patient">extracorporeal photopheresis</GlossaryTermRef> (ECP), the patient is given drugs and then some <GlossaryTermRef href="CDR0000270735" dictionary="Cancer.gov" audience="Patient">blood</GlossaryTermRef> cells are
			 taken from the body, put under a special <GlossaryTermRef href="CDR0000046700" dictionary="Cancer.gov" audience="Patient">ultraviolet A light</GlossaryTermRef>, and put back into the body. ECP may be used alone or combined with <GlossaryTermRef href="CDR0000439430" dictionary="Cancer.gov" audience="Patient">total skin electron beam (TSEB) radiation therapy</GlossaryTermRef>.</ListItem></ItemizedList></SummarySection><SummarySection id="_60"><KeyPoint id="_61">Radiation therapy</KeyPoint><Para id="_110"><GlossaryTermRef href="CDR0000044971" dictionary="Cancer.gov" audience="Patient">Radiation therapy</GlossaryTermRef> is a cancer treatment that uses high-energy <GlossaryTermRef href="CDR0000045944" dictionary="Cancer.gov" audience="Patient">x-rays</GlossaryTermRef> or other types of <GlossaryTermRef href="CDR0000045072" dictionary="Cancer.gov" audience="Patient">radiation</GlossaryTermRef> to kill cancer cells or keep them from growing. <GlossaryTermRef href="CDR0000046686" dictionary="Cancer.gov" audience="Patient">External radiation therapy</GlossaryTermRef> uses a machine outside the body to send radiation toward  the area of the body with cancer. Sometimes, total skin electron beam (TSEB) radiation therapy is used to treat mycosis fungoides and Sézary syndrome.  This is a type of external radiation treatment in which  a radiation therapy machine aims <GlossaryTermRef href="CDR0000702062" dictionary="Cancer.gov" audience="Patient">electrons</GlossaryTermRef> (tiny, invisible particles) at the skin covering the whole body . External radiation therapy may also be used as <GlossaryTermRef href="CDR0000045815" dictionary="Cancer.gov" audience="Patient">palliative therapy</GlossaryTermRef> to relieve <GlossaryTermRef href="CDR0000045022" dictionary="Cancer.gov" audience="Patient">symptoms</GlossaryTermRef> and improve <GlossaryTermRef href="CDR0000045417" dictionary="Cancer.gov" audience="Patient">quality of life</GlossaryTermRef>. </Para><Para id="_185"><GlossaryTermRef href="CDR0000666694" dictionary="Cancer.gov" audience="Patient">Ultraviolet A (UVA) radiation therapy</GlossaryTermRef> or <GlossaryTermRef href="CDR0000046700" dictionary="Cancer.gov" audience="Patient">ultraviolet B (UVB) radiation therapy</GlossaryTermRef>  may be given using a special lamp or laser that directs radiation at the skin.</Para></SummarySection><SummarySection id="_63"><KeyPoint id="_64">Chemotherapy</KeyPoint><Para id="_111"><GlossaryTermRef href="CDR0000045214" dictionary="Cancer.gov" audience="Patient">Chemotherapy</GlossaryTermRef> is a cancer treatment that uses drugs to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.   When chemotherapy is taken by mouth or injected into a vein or muscle, the drugs enter the bloodstream and can reach cancer cells throughout the body (<GlossaryTermRef href="CDR0000301626" dictionary="Cancer.gov" audience="Patient">systemic chemotherapy</GlossaryTermRef>).   Sometimes the chemotherapy is topical
			 (put on the skin in a cream, lotion, or <GlossaryTermRef href="CDR0000508685" dictionary="Cancer.gov" audience="Patient">ointment</GlossaryTermRef>). </Para><Para id="_165">See <ExternalRef xref="https://www.cancer.gov/about-cancer/treatment/drugs/non-hodgkin">Drugs Approved for Non-Hodgkin Lymphoma</ExternalRef> for more information. (Mycosis fungoides and Sézary syndrome are types of <GlossaryTermRef href="CDR0000045148" dictionary="Cancer.gov" audience="Patient">non-Hodgkin lymphoma</GlossaryTermRef>.)</Para></SummarySection><SummarySection id="_134"><KeyPoint id="_68">Other drug therapy</KeyPoint><Para id="_137"> Topical <GlossaryTermRef href="CDR0000045658" dictionary="Cancer.gov" audience="Patient">corticosteroids</GlossaryTermRef> are used to relieve red, swollen, and <GlossaryTermRef href="CDR0000044042" dictionary="Cancer.gov" audience="Patient">inflamed</GlossaryTermRef> skin. They are a type of <GlossaryTermRef href="CDR0000613764" dictionary="Cancer.gov" audience="Patient">steroid</GlossaryTermRef>. Topical corticosteroids  may be in a cream, lotion, or ointment. </Para><Para id="_112"><GlossaryTermRef href="CDR0000045870" dictionary="Cancer.gov" audience="Patient">Retinoids</GlossaryTermRef>, such as <GlossaryTermRef href="CDR0000045423" dictionary="Cancer.gov" audience="Patient">bexarotene</GlossaryTermRef>, are drugs related to <GlossaryTermRef href="CDR0000045248" dictionary="Cancer.gov" audience="Patient">vitamin A</GlossaryTermRef> that can slow the growth of certain types of cancer cells. The retinoids may be taken by mouth or put on the skin.</Para><Para id="_200"><GlossaryTermRef href="CDR0000393761" dictionary="Cancer.gov" audience="Patient">Lenalidomide</GlossaryTermRef> is a drug that helps the <GlossaryTermRef href="CDR0000046356" dictionary="Cancer.gov" audience="Patient">immune system</GlossaryTermRef> kill <GlossaryTermRef href="CDR0000044636" dictionary="Cancer.gov" audience="Patient">abnormal</GlossaryTermRef> blood cells or cancer cells and  may prevent the growth of new <GlossaryTermRef href="CDR0000045020" dictionary="Cancer.gov" audience="Patient">blood vessels</GlossaryTermRef> that tumors need to grow.</Para><Para id="_201"> <GlossaryTermRef href="CDR0000455153" dictionary="Cancer.gov" audience="Patient">Vorinostat</GlossaryTermRef> and <GlossaryTermRef href="CDR0000509038" dictionary="Cancer.gov" audience="Patient">romidepsin</GlossaryTermRef> are two of the <GlossaryTermRef href="CDR0000472896" dictionary="Cancer.gov" audience="Patient">histone deacetylase (HDAC) inhibitors</GlossaryTermRef> used to treat mycosis fungoides and  Sézary syndrome. HDAC inhibitors cause a chemical change that stops tumor cells from dividing.</Para><Para id="_169">See <ExternalRef xref="https://www.cancer.gov/about-cancer/treatment/drugs/non-hodgkin">Drugs Approved for Non-Hodgkin Lymphoma</ExternalRef> for more information. (Mycosis fungoides and Sézary syndrome are types of non-Hodgkin lymphoma.)</Para></SummarySection><SummarySection id="_135"><KeyPoint id="_132">Immunotherapy</KeyPoint><Para id="_131"><GlossaryTermRef href="CDR0000045729" dictionary="Cancer.gov" audience="Patient">Immunotherapy</GlossaryTermRef> is a treatment that uses the patient's <GlossaryTermRef href="CDR0000046356" dictionary="Cancer.gov" audience="Patient">immune system</GlossaryTermRef> to fight cancer.  Substances made by the body or made in a laboratory are used to boost, direct, or restore the body's natural defenses against cancer.  This cancer treatment is a type of <GlossaryTermRef href="CDR0000045617" dictionary="Cancer.gov" audience="Patient">biologic therapy</GlossaryTermRef>.</Para><ItemizedList id="_239" Style="bullet"><ListItem><GlossaryTermRef href="CDR0000045324" dictionary="Cancer.gov" audience="Patient">Interferon</GlossaryTermRef>: This treatment interferes with the division of mycosis
			 fungoides and Sézary cells and can slow
				<GlossaryTermRef href="CDR0000046634" dictionary="Cancer.gov" audience="Patient">tumor</GlossaryTermRef> growth.</ListItem></ItemizedList><Para id="_166">See <ExternalRef xref="https://www.cancer.gov/about-cancer/treatment/drugs/non-hodgkin">Drugs Approved for Non-Hodgkin Lymphoma</ExternalRef> for more information. (Mycosis fungoides and Sézary syndrome are types of non-Hodgkin lymphoma.)</Para></SummarySection><SummarySection id="_225"><KeyPoint id="_226">Targeted therapy</KeyPoint><Para id="_227"><GlossaryTermRef href="CDR0000270742" dictionary="Cancer.gov" audience="Patient">Targeted therapy</GlossaryTermRef> is a type of treatment that uses drugs or other substances to identify and attack specific cancer cells. Targeted therapies usually cause less harm to normal cells than chemotherapy or radiation therapy do.</Para><ItemizedList id="_240" Style="bullet"><ListItem> <GlossaryTermRef href="CDR0000046066" dictionary="Cancer.gov" audience="Patient">Monoclonal antibodies</GlossaryTermRef>: Monoclonal antibodies are immune system <GlossaryTermRef href="CDR0000046092" dictionary="Cancer.gov" audience="Patient">proteins</GlossaryTermRef> made in the laboratory to treat many diseases, including cancer. As a cancer treatment, these <GlossaryTermRef href="CDR0000044918" dictionary="Cancer.gov" audience="Patient">antibodies</GlossaryTermRef> can attach to a specific target on cancer cells or other cells that may help cancer cells grow. The antibodies are able to then kill the cancer cells, block their growth, or keep them from spreading. Monoclonal antibodies are given by <GlossaryTermRef href="CDR0000045738" dictionary="Cancer.gov" audience="Patient">infusion</GlossaryTermRef>. They may be used alone or to carry drugs, <GlossaryTermRef href="CDR0000046622" dictionary="Cancer.gov" audience="Patient">toxins</GlossaryTermRef>, or <GlossaryTermRef href="CDR0000046550" dictionary="Cancer.gov" audience="Patient">radioactive</GlossaryTermRef> material directly to cancer cells.<Para id="_235">Types of monoclonal antibodies include:</Para><ItemizedList id="_236" Style="bullet"><ListItem><GlossaryTermRef href="CDR0000710543" dictionary="Cancer.gov" audience="Patient">Brentuximab vedotin</GlossaryTermRef>, which contains a <GlossaryTermRef href="CDR0000046066" dictionary="Cancer.gov" audience="Patient">monoclonal antibody</GlossaryTermRef> that binds to a protein, called CD30, found on some types of  lymphoma cells. It also contains an anticancer drug that may help kill cancer cells.</ListItem><ListItem><GlossaryTermRef href="CDR0000794274" dictionary="Cancer.gov" audience="Patient">Mogamulizumab</GlossaryTermRef>, which contains a monoclonal antibody that binds to a <GlossaryTermRef href="CDR0000046092" dictionary="Cancer.gov" audience="Patient">protein</GlossaryTermRef>, called CCR4, found on some types of <GlossaryTermRef href="CDR0000045368" dictionary="Cancer.gov" audience="Patient">lymphoma</GlossaryTermRef> cells.  It may block this protein and help the immune system kill cancer cells. It  is  used to treat mycosis fungoides and  Sézary syndrome that came back or did not get better after treatment with at least one <GlossaryTermRef href="CDR0000045922" dictionary="Cancer.gov" audience="Patient">systemic therapy</GlossaryTermRef>.</ListItem></ItemizedList><EmbeddedVideo id="_252" ref="CDR0000801837" hosting="youtube" unique_id="dxnjAc-rqz8" language="en" audience="Patients" template="Video75NoTitle"><VideoTitle>monoclonal antibodies: how monoclonal antibodies treat cancer</VideoTitle><Caption language="en">How do  monoclonal antibodies work to treat cancer? This video shows how monoclonal antibodies, such as trastuzumab, pembrolizumab, and rituximab, block molecules cancer cells need to grow, flag cancer cells for destruction by the body’s immune system, or deliver harmful substances to cancer cells. </Caption></EmbeddedVideo></ListItem></ItemizedList></SummarySection><SummarySection id="_230"><KeyPoint id="_231">High-dose chemotherapy and radiation therapy with stem cell transplant</KeyPoint><Para id="_232">High <GlossaryTermRef href="CDR0000044664" dictionary="Cancer.gov" audience="Patient">doses</GlossaryTermRef> of chemotherapy and sometimes radiation therapy are given to kill cancer cells. Healthy cells, including blood-forming cells, are also destroyed by the cancer treatment. <GlossaryTermRef href="CDR0000046695" dictionary="Cancer.gov" audience="Patient">Stem cell transplant</GlossaryTermRef> is a treatment to replace the blood-forming cells. <GlossaryTermRef href="CDR0000046598" dictionary="Cancer.gov" audience="Patient">Stem cells</GlossaryTermRef> (immature blood cells) are removed from the blood or <GlossaryTermRef href="CDR0000045622" dictionary="Cancer.gov" audience="Patient">bone marrow</GlossaryTermRef> of the patient or a <GlossaryTermRef href="CDR0000643010" dictionary="Cancer.gov" audience="Patient">donor</GlossaryTermRef> and are frozen and stored. After the patient completes chemotherapy and radiation therapy, the stored stem cells are thawed and given back to the patient through an <GlossaryTermRef href="CDR0000045738" dictionary="Cancer.gov" audience="Patient">infusion</GlossaryTermRef>. These reinfused stem cells grow into (and restore) the body's blood cells.</Para></SummarySection></SummarySection><SummarySection id="_72"><SectMetaData><SectionType>Treatment in clinical trials</SectionType></SectMetaData><KeyPoint id="_73">New types of treatment are being tested in clinical
		  trials.</KeyPoint><Para id="_370">This summary section describes treatments that are being studied in clinical trials. It may not mention every new treatment being studied. Information about clinical trials is available from the <ExternalRef xref="https://www.cancer.gov/research/participate/clinical-trials">NCI website</ExternalRef>.</Para><SummarySection id="_371"><KeyPoint id="_376">Immune checkpoint inhibitor therapy</KeyPoint><ItemizedList id="_374" Style="bullet">
     <ListItem><GlossaryTermRef href="CDR0000772606" dictionary="Cancer.gov" audience="Patient">Immune checkpoint inhibitor</GlossaryTermRef> <GlossaryTermRef href="CDR0000044737" dictionary="Cancer.gov" audience="Patient">therapy</GlossaryTermRef>: Immune checkpoint inhibitors block <GlossaryTermRef href="CDR0000046092" dictionary="Cancer.gov" audience="Patient">proteins</GlossaryTermRef> called checkpoints that are made by some types of immune system cells, such as <GlossaryTermRef href="CDR0000044928" dictionary="Cancer.gov" audience="Patient">T cells</GlossaryTermRef>, and some cancer cells. These checkpoints help keep <GlossaryTermRef href="CDR0000045722" dictionary="Cancer.gov" audience="Patient">immune responses</GlossaryTermRef> from being too strong and sometimes can keep T cells from killing cancer cells. When these checkpoints are blocked, T cells can kill cancer cells better.</ListItem></ItemizedList><ItemizedList id="_375" Style="bullet">
     <ListItem><GlossaryTermRef href="CDR0000777027" dictionary="Cancer.gov" audience="Patient">PD-1</GlossaryTermRef> and <GlossaryTermRef href="CDR0000797389" dictionary="Cancer.gov" audience="Patient">PD-L1</GlossaryTermRef> inhibitor therapy: PD-1 is a protein on the surface of T cells that helps keep the body’s immune responses in check. PD-L1 is a protein found on some types of cancer cells. When PD-1 attaches to PD-L1, it stops the T cell from killing the cancer cell. PD-1 and PD-L1 inhibitors keep PD-1 and PD-L1 proteins from attaching to each other.  This allows the T cells to kill cancer cells. <GlossaryTermRef href="CDR0000764538" dictionary="Cancer.gov" audience="Patient">Pembrolizumab</GlossaryTermRef> is a type of PD-1 inhibitor.</ListItem></ItemizedList><MediaLink ref="CDR0000774646" type="image/jpeg" alt="Immune checkpoint inhibitor; the panel on the left shows the binding of proteins PD-L1 (on the tumor cell) to PD-1 (on the T cell), which keeps T cells from killing tumor cells in the body. Also shown are a tumor cell antigen and T cell receptor. The panel on the right shows immune checkpoint inhibitors (anti-PD-L1 and anti-PD-1) blocking the binding of PD-L1 to PD-1, which allows the T cells to kill tumor cells." language="en" placement="image-center" id="_331"><Caption language="en">Immune checkpoint inhibitor. Checkpoint proteins, such as PD-L1 on tumor cells and PD-1 on T cells, help keep immune responses in check. The binding of PD-L1 to PD-1 keeps T cells from killing tumor cells in the body (left panel). Blocking the binding of PD-L1 to PD-1 with an immune checkpoint inhibitor (anti-PD-L1 or anti-PD-1) allows the T cells to kill tumor cells (right panel).</Caption></MediaLink><EmbeddedVideo id="_369" ref="CDR0000795515" hosting="youtube" unique_id="GIUu239FWMg" language="en" audience="Patients" template="Video75NoTitle"><VideoTitle>immune checkpoint inhibitors</VideoTitle><Caption language="en">Immunotherapy uses the body’s immune system to fight cancer. This animation explains one type of immunotherapy that uses immune checkpoint inhibitors to treat cancer.</Caption></EmbeddedVideo></SummarySection><Para id="_144">Information about clinical trials is available from the    <ExternalRef xref="https://www.cancer.gov/research/participate/clinical-trials">NCI website</ExternalRef>.</Para></SummarySection><SummarySection id="_196"><KeyPoint id="_197">Treatment for mycosis fungoides and Sézary syndrome may cause side effects.</KeyPoint><Para id="_196_md_73">For information about <GlossaryTermRef href="CDR0000046580" dictionary="Cancer.gov" audience="Patient">side effects</GlossaryTermRef> caused by treatment for cancer, visit our <ExternalRef xref="https://www.cancer.gov/about-cancer/treatment/side-effects">Side Effects</ExternalRef> page.</Para></SummarySection><SummarySection id="_148"><KeyPoint id="_149">Patients may want to think about taking part in a clinical trial.</KeyPoint><Para id="_148_md_23">For some patients, taking part in a <GlossaryTermRef href="CDR0000045961" dictionary="Cancer.gov" audience="Patient">clinical trial</GlossaryTermRef> may be the best treatment choice. Clinical trials are part of the cancer research process. Clinical trials are done to find out if new cancer  treatments are safe and effective or better than the <GlossaryTermRef href="CDR0000044930" dictionary="Cancer.gov" audience="Patient">standard treatment</GlossaryTermRef>.</Para><Para id="_148_md_24">Many of today's standard treatments for cancer are based on earlier clinical trials. Patients who take part in a clinical trial may receive the standard treatment or be among the first  to receive a new treatment.</Para><Para id="_148_md_25">Patients who take part in clinical trials also help improve the way cancer will be treated in the future. Even when clinical trials do not lead to effective new treatments, they often answer important questions and help move research forward.</Para></SummarySection><SummarySection id="_150"><KeyPoint id="_151">Patients can enter clinical trials before, during, or after starting their cancer treatment.</KeyPoint><Para id="_150_md_29">Some clinical trials only include patients who have not yet received treatment. Other trials test treatments for patients whose cancer has not gotten better. There are also clinical trials that test new ways to stop cancer from recurring (coming back) or reduce the <GlossaryTermRef href="CDR0000046580" dictionary="Cancer.gov" audience="Patient">side effects</GlossaryTermRef> of cancer treatment.</Para><Para id="_150_md_30">Clinical trials are taking place in many parts of the country. Information about clinical trials supported by NCI can be found on NCI’s <ExternalRef xref="https://www.cancer.gov/research/participate/clinical-trials-search">clinical trials search</ExternalRef> webpage. Clinical trials supported by other organizations can be found on the <ExternalRef xref="https://clinicaltrials.gov/">ClinicalTrials.gov</ExternalRef> website.</Para></SummarySection><SummarySection id="_152"><KeyPoint id="_153">Follow-up tests may be needed.</KeyPoint><Para id="_152_md_33">As you go through treatment, you  will have follow-up tests or check-ups. Some tests that were done to <GlossaryTermRef href="CDR0000046450" dictionary="Cancer.gov" audience="Patient">diagnose</GlossaryTermRef> or <GlossaryTermRef href="CDR0000045885" dictionary="Cancer.gov" audience="Patient">stage</GlossaryTermRef> the cancer may be repeated to see how well the treatment is working. Decisions about whether to continue, change, or stop treatment may be based on the results of these tests.</Para><Para id="_152_md_34">Some of the tests will continue to be done from time to time after treatment has ended. The results of these tests can show if your condition has changed or if the cancer has recurred (come back). </Para></SummarySection></SummarySection><SummarySection id="_241"><SectMetaData><SpecificDiagnosis ref="CDR0000038224">stage I mycosis fungoides/Sezary syndrome</SpecificDiagnosis><SpecificDiagnosis ref="CDR0000038225">stage II mycosis fungoides/Sezary syndrome</SpecificDiagnosis><SectionType>Treatment options by stage</SectionType></SectMetaData><Title>Treatment of Stage I and Stage II Mycosis Fungoides</Title><Para id="_248">For information about the treatments listed below, see the <SummaryRef href="CDR0000258022#_233" url="/types/lymphoma/patient/mycosis-fungoides-treatment-pdq">Treatment Option Overview</SummaryRef> section.</Para><Para id="_81">Treatment of  newly diagnosed <GlossaryTermRef href="CDR0000454834" dictionary="Cancer.gov" audience="Patient">stage I</GlossaryTermRef> and <GlossaryTermRef href="CDR0000454837" dictionary="Cancer.gov" audience="Patient">stage II</GlossaryTermRef> mycosis fungoides may include the following:</Para><ItemizedList id="_189" Style="bullet"><ListItem><GlossaryTermRef href="CDR0000439423" dictionary="Cancer.gov" audience="Patient">Psoralen and ultraviolet A (PUVA) radiation therapy</GlossaryTermRef>.</ListItem><ListItem><GlossaryTermRef href="CDR0000666695" dictionary="Cancer.gov" audience="Patient">Ultraviolet B radiation</GlossaryTermRef> <GlossaryTermRef href="CDR0000044737" dictionary="Cancer.gov" audience="Patient">therapy</GlossaryTermRef>.</ListItem><ListItem><GlossaryTermRef href="CDR0000044971" dictionary="Cancer.gov" audience="Patient">Radiation therapy</GlossaryTermRef> with <GlossaryTermRef href="CDR0000439430" dictionary="Cancer.gov" audience="Patient">total skin electron beam radiation therapy</GlossaryTermRef>. In some cases, radiation therapy is given to skin <GlossaryTermRef href="CDR0000046324" dictionary="Cancer.gov" audience="Patient">lesions</GlossaryTermRef>, as <GlossaryTermRef href="CDR0000045815" dictionary="Cancer.gov" audience="Patient">palliative therapy</GlossaryTermRef> to reduce <GlossaryTermRef href="CDR0000046634" dictionary="Cancer.gov" audience="Patient">tumor</GlossaryTermRef> size to relieve <GlossaryTermRef href="CDR0000045022" dictionary="Cancer.gov" audience="Patient">symptoms</GlossaryTermRef> and improve <GlossaryTermRef href="CDR0000045417" dictionary="Cancer.gov" audience="Patient">quality of life</GlossaryTermRef>.</ListItem><ListItem>Immunotherapy given alone or combined with  <GlossaryTermRef href="CDR0000044737" dictionary="Cancer.gov" audience="Patient">therapy</GlossaryTermRef> directed at the skin.</ListItem><ListItem><GlossaryTermRef href="CDR0000046619" dictionary="Cancer.gov" audience="Patient">Topical chemotherapy</GlossaryTermRef>.</ListItem><ListItem><GlossaryTermRef href="CDR0000301626" dictionary="Cancer.gov" audience="Patient">Systemic chemotherapy</GlossaryTermRef> with one or more <GlossaryTermRef href="CDR0000348921" dictionary="Cancer.gov" audience="Patient">drugs</GlossaryTermRef>, which may be combined with therapy directed at the skin.</ListItem><ListItem>Other drug therapy (<GlossaryTermRef href="CDR0000045927" dictionary="Cancer.gov" audience="Patient">topical</GlossaryTermRef> <GlossaryTermRef href="CDR0000045658" dictionary="Cancer.gov" audience="Patient">corticosteroids</GlossaryTermRef>, <GlossaryTermRef href="CDR0000045870" dictionary="Cancer.gov" audience="Patient">retinoid</GlossaryTermRef> therapy, <GlossaryTermRef href="CDR0000393761" dictionary="Cancer.gov" audience="Patient">lenalidomide</GlossaryTermRef>, <GlossaryTermRef href="CDR0000472896" dictionary="Cancer.gov" audience="Patient">histone deacetylase inhibitors</GlossaryTermRef>).</ListItem><ListItem><GlossaryTermRef href="CDR0000270742" dictionary="Cancer.gov" audience="Patient">Targeted therapy</GlossaryTermRef> (<GlossaryTermRef href="CDR0000710543" dictionary="Cancer.gov" audience="Patient">brentuximab vedotin</GlossaryTermRef>).</ListItem></ItemizedList><Para id="_TrialSearch_241_19">Use our <ExternalRef xref="https://www.cancer.gov/research/participate/clinical-trials-search">clinical trial search</ExternalRef> to find NCI-supported cancer clinical trials that are accepting patients. You can search for trials based on the type of cancer, the age of the patient, and where the trials are being done. <ExternalRef xref="https://www.cancer.gov/research/participate/clinical-trials">General information</ExternalRef>  about clinical trials is also available.</Para></SummarySection><SummarySection id="_242"><SectMetaData><SpecificDiagnosis ref="CDR0000038226">stage III mycosis fungoides/Sezary syndrome</SpecificDiagnosis><SpecificDiagnosis ref="CDR0000038227">stage IV mycosis fungoides/Sezary syndrome</SpecificDiagnosis><SectionType>Treatment options by stage</SectionType></SectMetaData><Title>Treatment of Stage III and Stage IV Mycosis Fungoides (Including   Sézary Syndrome)</Title><Para id="_237">For information about the treatments listed below, see the <SummaryRef href="CDR0000258022#_233" url="/types/lymphoma/patient/mycosis-fungoides-treatment-pdq">Treatment Option Overview</SummaryRef> section.</Para><Para id="_87">Treatment of newly diagnosed <GlossaryTermRef href="CDR0000454840" dictionary="Cancer.gov" audience="Patient">stage III</GlossaryTermRef> and <GlossaryTermRef href="CDR0000454841" dictionary="Cancer.gov" audience="Patient">stage IV</GlossaryTermRef> mycosis fungoides
		  including Sézary syndrome is <GlossaryTermRef href="CDR0000045815" dictionary="Cancer.gov" audience="Patient">palliative</GlossaryTermRef> (to relieve <GlossaryTermRef href="CDR0000045022" dictionary="Cancer.gov" audience="Patient">symptoms</GlossaryTermRef> and improve the <GlossaryTermRef href="CDR0000045417" dictionary="Cancer.gov" audience="Patient">quality of life</GlossaryTermRef>)  and may include the following:</Para><ItemizedList id="_243" Style="bullet"><ListItem><GlossaryTermRef href="CDR0000439423" dictionary="Cancer.gov" audience="Patient">Psoralen and ultraviolet A (PUVA) radiation therapy</GlossaryTermRef>.</ListItem><ListItem><GlossaryTermRef href="CDR0000666695" dictionary="Cancer.gov" audience="Patient">Ultraviolet B radiation</GlossaryTermRef> <GlossaryTermRef href="CDR0000044737" dictionary="Cancer.gov" audience="Patient">therapy</GlossaryTermRef>.</ListItem><ListItem><GlossaryTermRef href="CDR0000403135" dictionary="Cancer.gov" audience="Patient">Extracorporeal photopheresis</GlossaryTermRef> (ECP) given alone or combined with <GlossaryTermRef href="CDR0000439430" dictionary="Cancer.gov" audience="Patient">total skin electron beam radiation therapy</GlossaryTermRef>.</ListItem><ListItem> <GlossaryTermRef href="CDR0000044971" dictionary="Cancer.gov" audience="Patient">Radiation therapy</GlossaryTermRef> with total skin electron beam radiation therapy. In some cases, radiation therapy is given to skin <GlossaryTermRef href="CDR0000046324" dictionary="Cancer.gov" audience="Patient">lesions</GlossaryTermRef>, as <GlossaryTermRef href="CDR0000045815" dictionary="Cancer.gov" audience="Patient">palliative therapy</GlossaryTermRef> to reduce <GlossaryTermRef href="CDR0000046634" dictionary="Cancer.gov" audience="Patient">tumor</GlossaryTermRef> size to  relieve <GlossaryTermRef href="CDR0000045022" dictionary="Cancer.gov" audience="Patient">symptoms</GlossaryTermRef> and improve <GlossaryTermRef href="CDR0000045417" dictionary="Cancer.gov" audience="Patient">quality of life</GlossaryTermRef>.</ListItem><ListItem>Immunotherapy given alone or combined with <GlossaryTermRef href="CDR0000044737" dictionary="Cancer.gov" audience="Patient">therapy</GlossaryTermRef> directed at the skin.</ListItem><ListItem><GlossaryTermRef href="CDR0000301626" dictionary="Cancer.gov" audience="Patient">Systemic chemotherapy</GlossaryTermRef> with one or more <GlossaryTermRef href="CDR0000348921" dictionary="Cancer.gov" audience="Patient">drugs</GlossaryTermRef>, which may be combined with therapy directed at the skin. </ListItem><ListItem><GlossaryTermRef href="CDR0000046619" dictionary="Cancer.gov" audience="Patient">Topical chemotherapy</GlossaryTermRef>.</ListItem><ListItem>Other drug therapy (<GlossaryTermRef href="CDR0000045927" dictionary="Cancer.gov" audience="Patient">topical</GlossaryTermRef> <GlossaryTermRef href="CDR0000045658" dictionary="Cancer.gov" audience="Patient">corticosteroids</GlossaryTermRef>, <GlossaryTermRef href="CDR0000393761" dictionary="Cancer.gov" audience="Patient">lenalidomide</GlossaryTermRef>, <GlossaryTermRef href="CDR0000045423" dictionary="Cancer.gov" audience="Patient">bexarotene</GlossaryTermRef>, <GlossaryTermRef href="CDR0000472896" dictionary="Cancer.gov" audience="Patient">histone deacetylase inhibitors</GlossaryTermRef>).</ListItem><ListItem><GlossaryTermRef href="CDR0000270742" dictionary="Cancer.gov" audience="Patient">Targeted therapy</GlossaryTermRef> with <GlossaryTermRef href="CDR0000710543" dictionary="Cancer.gov" audience="Patient">brentuximab vedotin</GlossaryTermRef>.</ListItem><ListItem>A <GlossaryTermRef href="CDR0000045961" dictionary="Cancer.gov" audience="Patient">clinical trial</GlossaryTermRef> of <GlossaryTermRef href="CDR0000772606" dictionary="Cancer.gov" audience="Patient">immune checkpoint inhibitor</GlossaryTermRef> therapy with <GlossaryTermRef href="CDR0000764538" dictionary="Cancer.gov" audience="Patient">pembrolizumab</GlossaryTermRef>.</ListItem></ItemizedList><Para id="_TrialSearch_242_19">Use our <ExternalRef xref="https://www.cancer.gov/research/participate/clinical-trials-search">clinical trial search</ExternalRef> to find NCI-supported cancer clinical trials that are accepting patients. You can search for trials based on the type of cancer, the age of the patient, and where the trials are being done. <ExternalRef xref="https://www.cancer.gov/research/participate/clinical-trials">General information</ExternalRef>  about clinical trials is also available.</Para></SummarySection><SummarySection id="_244"><SectMetaData><SpecificDiagnosis ref="CDR0000038228">recurrent mycosis fungoides/Sezary syndrome</SpecificDiagnosis><SectionType>Treatment options for recurrent cancer</SectionType></SectMetaData><Title>Treatment  Recurrent Mycosis Fungoides (Including and   Sézary Syndrome)</Title><Para id="_245">For information about the treatments listed below, see the <SummaryRef href="CDR0000258022#_233" url="/types/lymphoma/patient/mycosis-fungoides-treatment-pdq">Treatment Option Overview</SummaryRef> section.</Para><Para id="_246">Treatment of <GlossaryTermRef href="CDR0000045862" dictionary="Cancer.gov" audience="Patient">recurrent</GlossaryTermRef>
		<GlossaryTermRef href="CDR0000045794" dictionary="Cancer.gov" audience="Patient">mycosis fungoides</GlossaryTermRef> including <GlossaryTermRef href="CDR0000045878" dictionary="Cancer.gov" audience="Patient">Sézary syndrome</GlossaryTermRef> may be  within a clinical trial and may include the
		following:</Para><ItemizedList id="_247" Style="bullet"><ListItem><GlossaryTermRef href="CDR0000044971" dictionary="Cancer.gov" audience="Patient">Radiation therapy</GlossaryTermRef>  with  <GlossaryTermRef href="CDR0000439430" dictionary="Cancer.gov" audience="Patient">total skin electron beam radiation therapy</GlossaryTermRef>. In some cases, radiation therapy is given to skin <GlossaryTermRef href="CDR0000046324" dictionary="Cancer.gov" audience="Patient">lesions</GlossaryTermRef> as <GlossaryTermRef href="CDR0000045815" dictionary="Cancer.gov" audience="Patient">palliative therapy</GlossaryTermRef> to reduce <GlossaryTermRef href="CDR0000046634" dictionary="Cancer.gov" audience="Patient">tumor</GlossaryTermRef> size to relieve <GlossaryTermRef href="CDR0000045022" dictionary="Cancer.gov" audience="Patient">symptoms</GlossaryTermRef> and improve <GlossaryTermRef href="CDR0000045417" dictionary="Cancer.gov" audience="Patient">quality of life</GlossaryTermRef>.</ListItem><ListItem><GlossaryTermRef href="CDR0000439423" dictionary="Cancer.gov" audience="Patient">Psoralen and ultraviolet A (PUVA) radiation therapy</GlossaryTermRef>, which may be given with immunotherapy.</ListItem><ListItem><GlossaryTermRef href="CDR0000666695" dictionary="Cancer.gov" audience="Patient">Ultraviolet B radiation</GlossaryTermRef>.</ListItem><ListItem><GlossaryTermRef href="CDR0000403135" dictionary="Cancer.gov" audience="Patient">Extracorporeal photopheresis</GlossaryTermRef> (ECP).</ListItem><ListItem><GlossaryTermRef href="CDR0000301626" dictionary="Cancer.gov" audience="Patient">Systemic chemotherapy</GlossaryTermRef> with one or more <GlossaryTermRef href="CDR0000348921" dictionary="Cancer.gov" audience="Patient">drugs</GlossaryTermRef>.</ListItem><ListItem>Other drug <GlossaryTermRef href="CDR0000044737" dictionary="Cancer.gov" audience="Patient">therapy</GlossaryTermRef> (<GlossaryTermRef href="CDR0000045927" dictionary="Cancer.gov" audience="Patient">topical</GlossaryTermRef> <GlossaryTermRef href="CDR0000045658" dictionary="Cancer.gov" audience="Patient">corticosteroids</GlossaryTermRef>, <GlossaryTermRef href="CDR0000045870" dictionary="Cancer.gov" audience="Patient">retinoid</GlossaryTermRef> therapy, <GlossaryTermRef href="CDR0000393761" dictionary="Cancer.gov" audience="Patient">lenalidomide</GlossaryTermRef>, <GlossaryTermRef href="CDR0000472896" dictionary="Cancer.gov" audience="Patient">histone deacetylase inhibitors</GlossaryTermRef>).</ListItem><ListItem>Immunotherapy given alone or combined with therapy directed at the skin.</ListItem><ListItem><GlossaryTermRef href="CDR0000346522" dictionary="Cancer.gov" audience="Patient">High-dose chemotherapy</GlossaryTermRef>, and sometimes radiation therapy, with <GlossaryTermRef href="CDR0000046695" dictionary="Cancer.gov" audience="Patient">stem cell transplant</GlossaryTermRef>.</ListItem><ListItem><GlossaryTermRef href="CDR0000270742" dictionary="Cancer.gov" audience="Patient">Targeted therapy</GlossaryTermRef> (<GlossaryTermRef href="CDR0000710543" dictionary="Cancer.gov" audience="Patient">brentuximab vedotin</GlossaryTermRef> or <GlossaryTermRef href="CDR0000794274" dictionary="Cancer.gov" audience="Patient">mogamulizumab</GlossaryTermRef>).</ListItem></ItemizedList><Para id="_TrialSearch_244_19">Use our <ExternalRef xref="https://www.cancer.gov/research/participate/clinical-trials-search">clinical trial search</ExternalRef> to find NCI-supported cancer clinical trials that are accepting patients. You can search for trials based on the type of cancer, the age of the patient, and where the trials are being done. <ExternalRef xref="https://www.cancer.gov/research/participate/clinical-trials">General information</ExternalRef>  about clinical trials is also available.</Para></SummarySection><SummarySection id="_141"><Title>To Learn More About Mycosis Fungoides Sézary Syndrome</Title><Para id="_138">For more information from the <GlossaryTermRef href="CDR0000044266" dictionary="Cancer.gov" audience="Patient">National Cancer Institute</GlossaryTermRef> about  mycosis fungoides and Sézary syndrome, see the following:</Para><ItemizedList id="_168" Style="bullet"><ListItem><ExternalRef xref="https://www.cancer.gov/types/lymphoma">Lymphoma  Home Page</ExternalRef></ListItem><ListItem><ExternalRef xref="https://www.cancer.gov/about-cancer/treatment/types/photodynamic-therapy">Photodynamic Therapy for Cancer</ExternalRef></ListItem><ListItem><ExternalRef xref="https://www.cancer.gov/about-cancer/treatment/drugs/non-hodgkin">Drugs Approved for Non-Hodgkin Lymphoma</ExternalRef></ListItem><ListItem><ExternalRef xref="https://www.cancer.gov/about-cancer/treatment/types/immunotherapy">Immunotherapy to Treat Cancer</ExternalRef></ListItem><ListItem><ExternalRef xref="https://www.cancer.gov/about-cancer/treatment/types/targeted-therapies">Targeted Cancer Therapies</ExternalRef></ListItem></ItemizedList><Para id="_141_md_40">For general cancer information and other resources from the National Cancer Institute, visit:</Para><ItemizedList id="_141_md_41" Style="bullet"><ListItem><ExternalRef xref="https://www.cancer.gov/about-cancer">About Cancer</ExternalRef></ListItem><ListItem><ExternalRef xref="https://www.cancer.gov/about-cancer/diagnosis-staging/staging">Cancer Staging</ExternalRef></ListItem><ListItem><ExternalRef xref="https://www.cancer.gov/publications/patient-education/chemo-and-you">Chemotherapy and You: Support for People With Cancer</ExternalRef></ListItem><ListItem><ExternalRef xref="https://www.cancer.gov/publications/patient-education/radiation-therapy-and-you">Radiation Therapy and You: Support for People With Cancer</ExternalRef></ListItem><ListItem><ExternalRef xref="https://www.cancer.gov/about-cancer/coping">Coping with Cancer</ExternalRef></ListItem><ListItem><ExternalRef xref="https://www.cancer.gov/about-cancer/coping/questions">Questions to Ask Your Doctor about Cancer</ExternalRef></ListItem><ListItem><ExternalRef xref="https://cancercontrol.cancer.gov/ocs/resources/survivors.html">For Survivors, Caregivers, and Advocates</ExternalRef></ListItem></ItemizedList></SummarySection><SummarySection id="_AboutThis_1"><Title>About This PDQ Summary</Title><SummarySection id="_AboutThis_2"><Title>About PDQ</Title><Para id="_AboutThis_3">Physician Data Query (PDQ) is the National Cancer Institute's (NCI's) comprehensive cancer information database. The PDQ database contains summaries of the latest published information on cancer prevention, detection, genetics, treatment, supportive care, and complementary and alternative medicine. Most summaries come in two versions. The health professional versions have detailed information written in technical language. The patient versions are written in easy-to-understand, nontechnical language. Both versions have cancer information that is accurate and up to date and most versions are also available in <ExternalRef xref="https://www.cancer.gov/espanol/publicaciones/pdq">Spanish</ExternalRef>.</Para><Para id="_AboutThis_4">PDQ is a service of the NCI. The NCI is part of the National Institutes of Health (NIH). NIH is the federal government’s center of biomedical research.  The PDQ summaries are based on an independent review of the medical literature. They are not policy statements of the NCI or the NIH.</Para></SummarySection><SummarySection id="_AboutThis_5"><Title>Purpose of This Summary</Title><Para id="_AboutThis_6">This PDQ cancer information summary has current information about the treatment of mycosis fungoides (including Sézary  Syndrome).  It is meant to inform and help patients, families, and caregivers. It does not give formal guidelines or recommendations for making decisions about health care.</Para></SummarySection><SummarySection id="_AboutThis_7"><Title>Reviewers and Updates</Title><Para id="_AboutThis_8">Editorial Boards write the PDQ cancer information summaries and keep them up to date. These Boards are made up of experts in cancer treatment and other specialties related to cancer. The summaries are reviewed regularly and changes are made when there is new information. The date on each summary ("Updated") is the date of the most recent change.
</Para><Para id="_AboutThis_9">The information in this patient summary was taken from the health professional version, which is reviewed regularly and updated as needed, by the <ExternalRef xref="https://www.cancer.gov/publications/pdq/editorial-boards/adult-treatment">PDQ Adult Treatment Editorial Board</ExternalRef>.
</Para></SummarySection><SummarySection id="_AboutThis_10"><Title>Clinical Trial Information</Title><Para id="_AboutThis_11">A clinical trial is a study to answer a scientific question, such as whether one treatment is better than another. Trials are based on past studies and what has been learned in the laboratory. Each trial answers certain scientific questions in order to find new and better ways to help cancer patients. During treatment clinical trials, information is collected about the effects of a new treatment and how well it works. If a clinical trial shows that a new treatment is better than one currently being used, the new treatment may become "standard." Patients may want to think about taking part in a clinical trial. Some clinical trials are open only to patients who have not started treatment.
</Para><Para id="_AboutThis_12">Clinical trials can be found online at <ExternalRef xref="https://www.cancer.gov/research/participate/clinical-trials">NCI's website</ExternalRef>. For more information, call the <ExternalRef xref="https://www.cancer.gov/contact/contact-center">Cancer Information Service</ExternalRef> (CIS), NCI's contact center, at 1-800-4-CANCER (1-800-422-6237).
</Para></SummarySection><SummarySection id="_AboutThis_13"><Title>Permission to Use This Summary</Title><Para id="_AboutThis_14">PDQ is a registered trademark. The content of PDQ documents can be used freely as text. It cannot be identified as an NCI PDQ cancer information summary unless the whole summary is shown and it is updated regularly. However, a user would be allowed to write a sentence such as “NCI’s PDQ cancer information summary about breast cancer prevention states the risks in the following way: [include excerpt from the summary].”
</Para><Para id="_AboutThis_15">The best way to cite this PDQ summary is:</Para><Para id="_AboutThis_21">PDQ® Adult Treatment Editorial Board. PDQ Mycosis Fungoides (Including Sézary Syndrome) Treatment. Bethesda, MD: National Cancer Institute. Updated  &lt;MM/DD/YYYY&gt;. Available at: <ExternalRef xref="https://www.cancer.gov/types/lymphoma/patient/mycosis-fungoides-treatment-pdq">https://www.cancer.gov/types/lymphoma/patient/mycosis-fungoides-treatment-pdq</ExternalRef>.  Accessed &lt;MM/DD/YYYY&gt;. [PMID: 26389317]</Para><Para id="_AboutThis_16">Images in this summary are used with permission of the author(s), artist, and/or publisher for use in the PDQ summaries only. If you want to use an image from a PDQ summary and you are not using the whole summary, you must get permission from the owner. It cannot be given by the National Cancer Institute. Information about using the images in this summary, along with many other images related to cancer can be found in <ExternalRef xref="https://visualsonline.cancer.gov/">Visuals Online</ExternalRef>. Visuals Online is a collection of more than 3,000 scientific images.
</Para></SummarySection><SummarySection id="_AboutThis_17"><Title>Disclaimer</Title><Para id="_AboutThis_18">The information in these summaries should not be used to make decisions about insurance reimbursement. More information on insurance coverage is available on Cancer.gov on the <ExternalRef xref="https://www.cancer.gov/about-cancer/managing-care">Managing Cancer Care</ExternalRef> page.</Para></SummarySection><SummarySection id="_AboutThis_19"><Title>Contact Us</Title><Para id="_AboutThis_20">More information about contacting us or receiving help with the Cancer.gov website can be found on our <ExternalRef xref="https://www.cancer.gov/contact">Contact Us for Help</ExternalRef> page. Questions can also be submitted to Cancer.gov through the website’s <ExternalRef xref="https://www.cancer.gov/contact/email-us">E-mail Us</ExternalRef>.</Para></SummarySection></SummarySection><PatientVersionOf ref="CDR0000062881"/><DateLastModified>2025-02-12</DateLastModified></Summary>
